Please login to the form below

Not currently logged in
Email:
Password:

aspirin

This page shows the latest aspirin news and features for those working in and with pharma, biotech and healthcare.

Aspirin to be trialled as part of new treatment for triple negative breast cancer

Aspirin to be trialled as part of new treatment for triple negative breast cancer

The trial follows prior research demonstrating that, in mice, pairing an immunotherapy drug like avelumab with aspirin helps to control tumour growth more successfully than immunotherapy drugs alone. ... The trial will be the first to test if aspirin can

Latest news

  • AstraZeneca’s Brilinta reduces rate of secondary stroke AstraZeneca’s Brilinta reduces rate of secondary stroke

    Detailed results from the phase 3 THALES trial also showed that Brilinta, given at a dose of 90mg twice-daily alongside aspirin, significantly reduced the rate of ischaemic stroke by 21%, ... The drug also reduced the risk for severe bleeding events –

  • AZ says Brilinta hits the mark in new stroke trial AZ says Brilinta hits the mark in new stroke trial

    This time round, AZ evaluated Brilinta (ticagrelor) at a dose of 90-mg twice-daily, taken with aspirin for 30 days, in the phase 3 THALES trial. ... AZ has already tried to prove Brilinta’s benefit over aspirin in preventing stroke, but failed to do so

  • AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

    The study demonstrated that Brilinta plus aspirin reduced the risk of cardiovascular death, heart attack or stroke by 10% compared to aspirin alone.

  • AZ says Brilinta hits the mark in diabetic heart disease AZ says Brilinta hits the mark in diabetic heart disease

    The study showed that in diabetics with CAD and no prior history of heart attack or stroke, Brilinta given on top of aspirin therapy achieved a statistically-significant reduction in a ... Last year, the GLOBAL LEADERS study last year also showed that

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    low-dose aspirin, which is commonly prescribed for this purpose, but failed to hit the mark at the interim stage. ... While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm,

More from news
Approximately 2 fully matching, plus 71 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Natasha Giordano joins PLx Pharma Natasha Giordano joins PLx Pharma

    We are confident Natasha will be a driving force for PLx as we transition from the development phase to the commercial launch of our lead product, PL2200 Aspirin.”. ... I look forward to building on the compelling clinical data and initial market

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....